Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 0.98 |
| ▸ | KDR | P35968 | 3/20 | 0.98 |
| ▸ | BRAF | P15056 | 2/20 | 0.98 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.98 |
| ▸ | FLT4 | P35916 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.98 |
| ▸ | STK17B | O94768 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL30887946 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL11776 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL8208642 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL7866 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL465143 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351046 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351336 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL2770155 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28098790 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20230270826-A1 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | DELTA 4 GMBH (AT) | 2023-08-31 | — | — | US | disclosed |
| EP-4188355-A2 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | Delta 4 GmbH (AT) | 2023-06-07 | — | — | EP | disclosed |
| US-20220288231-A1 | METHODS AND COMPOSITIONS FOR REDUCING GENE OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSES | GENERATION BIO CO. | 2022-09-15 | — | — | US | disclosed |
| WO-2022023533-A2 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | DELTA 4 GMBH (AT) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288231-A1 | METHODS AND COMPOSITIONS FOR REDUCING GENE OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSES | TSG101, STING1, EIF2AK2 | EGFR 186/4885KDR 336/4885BRAF 304/4885 |
| US-20230270826-A1 | ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB | GLP1R, SLC5A1, DPP4 | EGFR 80/4885KDR 753/4885BRAF 742/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | EGFR 4765/4885KDR 4542/4885BRAF 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.